logo
Plus   Neg
Share
Email

Sensient Technologies Lowers FY19 EPS Guidance - Quick Facts

While reporting financial results for the second quarter, Sensient Technologies Corp. (SXT), a maker of colors, flavors and fragrances, on Friday lowered its guidance for earnings for the full year 2019.

For fiscal 2019, the company now anticipates that local currency earnings per share will be down 12 to 13 percent from the 2018 earnings per share of $3.70. Previously, the Company indicated that local currency earnings per share would be down 8 to 11 percent. In addition, the Company continues to expect a negative foreign currency impact of 1 to 2 percent, or about 5 cents per share.

Further, the Company now anticipates that local currency earnings per share will be down 8 to 9 percent from 2018 adjusted diluted earnings per share of $3.55. Previously, the Company indicated that local currency earnings per share would be down 4 to 7 percent. In addition, the Company continues to expect a negative foreign currency impact of 1 to 2 percent, or about 5 cents per share.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $3.29 per share for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
RELATED NEWS
Follow RTT